stockrowInteger Holdings Corporation
ITGR Healthcare Medical Devices
Integer Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, up 7.98% from fiscal 2024.
- Revenue
- −3.86%
- EPS
- −61.0%
- Free cash flow
- −65.2%
- Total debt
- +4.06%
Quarter to September 2026, against a year earlier
Follow ITGR
Alert me
Integer Holdings Corporation (ITGR) EPS (diluted)
Integer Holdings Corporation's EPS (diluted) for fiscal 2025 was $2.89, down 14.0% from $3.36 in fiscal 2024. Over the twelve months to 30 September 2026 it was $2.98. Over the past ten years it has ranged from −$0.29 (fiscal 2015) to $5.15 (fiscal 2018); the current reading is higher than 64% of that period. Integer Holdings Corporation ranks 15th of 147 Medical Devices companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $2.89 | (13.99%) |
| FY2024 | $3.36 | 24.91% |
| FY2023 | $2.69 | 35.18% |
| FY2022 | $1.99 | (31.62%) |
| FY2021 | $2.91 | 24.89% |
| FY2020 | $2.33 | (20.21%) |
| FY2019 | $2.92 | (43.30%) |
| FY2018 | $5.15 | 146.41% |
| FY2017 | $2.09 | 1,000.00% |
| FY2016 | $0.19 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.43 | (37.28%) |
| Jun 2026 | $0.69 | 43.75% |
| Mar 2026 | $0.48 | (65.22%) |
| Dec 2025 | $1.38 | 24.32% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| UFPT UFP Technologies, Inc. compare | $9.81 |
| TMDX TransMedics Group, Inc. compare | $3.69 |
| LIVN LivaNova PLC compare | $3.49 |
| ITGR Integer Holdings Corporation | $2.98 |
| HAE Haemonetics Corporation compare | $2.23 |
| NEOG Neogen Corporation compare | −$0.25 |
| TXG 10x Genomics compare | −$0.59 |
| AXGN AxoGen, Inc. compare | −$0.65 |
| IRTC iRhythm Holdings, Inc. compare | −$1.17 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on ITGR
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement